Brentview Investment Management LLC Sells 764 Shares of Medtronic PLC $MDT

Brentview Investment Management LLC reduced its holdings in Medtronic PLC (NYSE:MDT) by 1.9% during the second quarter, Holdings Channel.com reports. The institutional investor owned 39,519 shares of the medical technology company’s stock after selling 764 shares during the quarter. Brentview Investment Management LLC’s holdings in Medtronic were worth $3,445,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Gilbert & Cook Inc. boosted its holdings in Medtronic by 1.9% in the second quarter. Gilbert & Cook Inc. now owns 6,103 shares of the medical technology company’s stock valued at $532,000 after acquiring an additional 114 shares in the last quarter. Red Spruce Capital LLC lifted its position in shares of Medtronic by 0.5% in the 2nd quarter. Red Spruce Capital LLC now owns 23,707 shares of the medical technology company’s stock worth $2,067,000 after purchasing an additional 118 shares during the period. Certior Financial Group LLC boosted its stake in shares of Medtronic by 3.7% during the 1st quarter. Certior Financial Group LLC now owns 3,450 shares of the medical technology company’s stock valued at $310,000 after purchasing an additional 122 shares in the last quarter. PrairieView Partners LLC boosted its stake in shares of Medtronic by 3.6% during the 2nd quarter. PrairieView Partners LLC now owns 3,726 shares of the medical technology company’s stock valued at $324,000 after purchasing an additional 128 shares in the last quarter. Finally, Baker Avenue Asset Management LP increased its position in shares of Medtronic by 3.1% during the first quarter. Baker Avenue Asset Management LP now owns 4,558 shares of the medical technology company’s stock valued at $410,000 after buying an additional 136 shares during the period. Institutional investors own 82.06% of the company’s stock.

Analyst Ratings Changes

MDT has been the subject of several research analyst reports. The Goldman Sachs Group set a $111.00 price objective on shares of Medtronic and gave the stock a “neutral” rating in a report on Wednesday, November 19th. Jefferies Financial Group restated a “hold” rating and issued a $110.00 target price on shares of Medtronic in a research note on Wednesday, November 19th. Argus lifted their price target on Medtronic from $105.00 to $115.00 and gave the company a “buy” rating in a research report on Tuesday, August 26th. Citigroup increased their price objective on Medtronic from $101.00 to $112.00 and gave the stock a “buy” rating in a report on Tuesday, October 7th. Finally, Truist Financial boosted their target price on shares of Medtronic from $103.00 to $110.00 and gave the company a “hold” rating in a report on Thursday, November 20th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and twelve have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $110.44.

Insider Buying and Selling

In related news, EVP Harry Skip Kiil sold 8,605 shares of the stock in a transaction dated Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total transaction of $788,045.90. Following the sale, the executive vice president directly owned 35,615 shares of the company’s stock, valued at approximately $3,261,621.70. This represents a 19.46% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 0.26% of the company’s stock.

Medtronic Stock Down 0.5%

MDT stock opened at $104.53 on Monday. The business has a 50 day moving average of $96.06 and a 200 day moving average of $91.71. The firm has a market cap of $134.00 billion, a PE ratio of 28.79, a price-to-earnings-growth ratio of 2.42 and a beta of 0.77. Medtronic PLC has a twelve month low of $79.29 and a twelve month high of $106.33. The company has a quick ratio of 1.50, a current ratio of 2.01 and a debt-to-equity ratio of 0.54.

Medtronic (NYSE:MDT) last released its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, topping analysts’ consensus estimates of $1.31 by $0.05. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.The firm had revenue of $8.96 billion for the quarter, compared to analysts’ expectations of $8.86 billion. During the same period in the prior year, the firm posted $1.26 earnings per share. The company’s quarterly revenue was up 6.6% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, research analysts forecast that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.